Back
Effects of Obesity on Posaconazole Kinetics in a Patient with Graft versus Host Disease
Justin J. Pettis, Stephanie R. Hyche, Katherine N. Logan, Arash Poursina, P. Brandon Bookstaver
Pharmacol. Pharm. Vol.4 No.2, April 18, 2013  DOI: 10.4236/pp.2013.42034
       (PDF  149K)     HTML      XML
Validated Gradient Stability Indicating UPLC Method for the Determination of Related Substances of Posaconazole in Bulk Drug
Vadlamanu Durga Prasad, Vanga Ranga Reddy, Pasula Aparna
Am. J. Anal. Chem. Vol.6 No.12, November 30, 2015  DOI: 10.4236/ajac.2015.612092
       (PDF  1471K)     HTML      XML
Pharmacokinetic/Pharmacodynamic Analysis the Probability of Target Attainment of Posaconazole against Mucorales Species in Patients with Mucormycosis
Ying Wang, Jingyi Zhao, Yinhui Yao, Junhui Hu, Jiuli Hu, Xu Xiao, Yanwu Zhao
Pharmacol. Pharm. Vol.11 No.5, May 15, 2020  DOI: 10.4236/pp.2020.115007
       (PDF  775K)     HTML      XML
Therapeutic Drug Monitoring of Chelating Agent Deferoxamine for β-Thalassemia Major Patients
Rawa Ratha, Tagreed Altaei
Int. J. Clin. Med. Vol.4 No.8, July 25, 2013  DOI: 10.4236/ijcm.2013.48059
       (PDF  1156K)     HTML     
Analysis of Pharmacokinetic/Pharmacodynamic Parameters and Dosage Regimen of Posaconazole against Candida spp. and Aspergillus spp. Using Monte Carlo Simulation
Ying Wang, Jingyi Zhao, Junhui Hu, Xinhong Zhao, Yinhui Yao
Pharmacol. Pharm. Vol.11 No.1, January 17, 2020  DOI: 10.4236/pp.2020.111003
       (PDF  1188K)     HTML      XML
 
 
Top